NMS · Financial Statements

PTC Therapeutics, Inc. (PTCT) Revenue, Earnings & Financial Statements

$60.36 NMS: PTCT Market Cap $5.04B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

PTC Therapeutics, Inc. most recently reported annual revenue of $1.7B, net profit of $683.0M. Revenue grew at an average annual rate of 35.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

PTC Therapeutics, Inc.: Revenue rose from $83.0M in 2016 to $1.7B in 2025, a change of +1985.5% over 9 years; net profit was positive in 1 of 10 reported years; operating margin moved from -159.7% to 49.5%, a shift of +209.2 percentage points; the most recent year shows net profit of $683.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$83.0M$194.0M$265.0M$307.0M$381.0M$539.0M$699.0M$938.0M$807.0M$1.7B
Operating Expenses$215.0M$259.0M$380.0M$548.0M$813.0M$913.0M$1.1B$1.4B$1.1B$874.0M
Operating Profit−$132.0M−$64.0M−$116.0M−$241.0M−$432.0M−$374.0M−$447.0M−$440.0M−$303.0M$857.0M
Operating Margin-159.7%-33.1%-43.7%-78.6%-113.4%-69.5%-64.0%-46.9%-37.5%49.5%
Other Income−$9.0M−$13.0M−$12.0M$1.0M$29.0M−$144.0M−$140.0M−$257.0M−$61.0M−$160.0M
Interest$8.0M$12.0M$13.0M$12.0M$56.0M$86.0M$91.0M$129.0M$167.0M$152.0M
Depreciation$3.0M$18.0M$26.0M$32.0M$43.0M$64.0M$129.0M$237.0M$76.0M$39.0M
Profit Before Tax−$142.0M−$78.0M−$128.0M−$240.0M−$403.0M−$518.0M−$587.0M−$696.0M−$363.0M$697.0M
Tax rate (%)-0.4%-1.7%0.0%-4.9%-8.7%-1.1%4.8%10.0%-0.1%2.0%
Net Profit−$142.0M−$79.0M−$128.0M−$252.0M−$438.0M−$524.0M−$559.0M−$627.0M−$363.0M$683.0M
EPS−$4.17−$2.02−$2.75−$4.27−$6.64−$7.43−$7.79−$8.37−$4.73$7.78

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$307.0M$210.0M$187.0M$197.0M$213.0M$1.2B$179.0M$211.0M$165.0M$273.0M$361.0M$358.0M
Operating Expenses$304.0M$256.0M$227.0M$251.0M$376.0M$206.0M$214.0M$208.0M$246.0M$227.0M$212.0M$333.0M
Operating Profit$3.0M−$45.0M−$40.0M−$55.0M−$162.0M$970.0M−$35.0M$3.0M−$82.0M$46.0M$149.0M$25.0M
Operating Margin1.0%-21.6%-21.5%-27.7%-76.2%82.5%-19.5%1.4%-49.6%16.8%41.3%7.0%
Interest$44.0M$41.0M$43.0M$42.0M$41.0M$34.0M$30.0M$33.0M$55.0M$49.0M$48.0M$46.0M
Profit Before Tax−$157.0M−$85.0M−$86.0M−$98.0M−$95.0M$930.0M−$71.0M−$23.0M−$139.0M−$2.0M$98.0M−$41.0M
Tax rate (%)0.8%-8.1%-15.7%-8.8%30.4%6.8%8.7%168.9%3.0%-14.1%14.4%-25.8%
Net Profit−$156.0M−$92.0M−$99.0M−$107.0M−$66.0M$867.0M−$65.0M$16.0M−$135.0M−$3.0M$83.0M−$52.0M
EPS−$2.06−$1.20−$1.29−$1.39−$0.85$10.04−$0.83$0.20−$1.67−$0.03$0.92−$0.62

Over the 10 years reported for PTC Therapeutics, Inc., borrowings increased from $98.0M in 2016 to $2.7B in 2025, cash stood at $985.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.35 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$269.0M$392.0M$1.1B$1.6B$2.2B$1.9B$1.7B$1.9B$1.7B$2.9B
Current Assets$261.0M$249.0M$321.0M$779.0M$1.2B$954.0M$694.0M$1.2B$1.4B$2.3B
Cash$232.0M$191.0M$228.0M$288.0M$209.0M$190.0M$280.0M$594.0M$780.0M$985.0M
Inventory$0$11.0M$16.0M$19.0M$19.0M$16.0M$22.0M$31.0M$23.0M$80.0M
Receivables$25.0M$40.0M$68.0M$56.0M$70.0M$110.0M$156.0M$161.0M$159.0M$182.0M
Fixed Assets$7.0M$8.0M$13.0M$35.0M$118.0M$130.0M$175.0M$179.0M$118.0M$135.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$399.0M$895.0M$584.0M$131.0M$283.0M$360.0M$961.0M
Other Assets$0$0$82.0M$82.0M$82.0M$82.0M$82.0M$82.0M$82.0M$82.0M
Total Liabilities$150.0M$235.0M$768.0M$1.0B$1.7B$1.9B$2.1B$2.7B$2.8B$3.1B
Current Liabilities$50.0M$82.0M$167.0M$236.0M$277.0M$509.0M$406.0M$603.0M$581.0M$968.0M
Borrowings$98.0M$145.0M$153.0M$328.0M$420.0M$1.3B$1.5B$2.2B$2.5B$2.7B
Other Liabilities$52.0M$90.0M$615.0M$701.0M$1.3B$667.0M$591.0M$485.0M$332.0M$397.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$120.0M$156.0M$351.0M$594.0M$482.0M$1.0M−$347.0M−$819.0M−$1.1B−$205.0M

For PTC Therapeutics, Inc., operating cash flow was positive in 1 of 10 reported years; free cash flow in the latest year was $411.0M; free cash flow was positive in 1 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow−$104.0M−$10.0M−$28.0M−$99.0M−$194.0M−$251.0M−$357.0M−$158.0M−$108.0M$711.0M
Investing Cash Flow$209.0M$26.0M−$45.0M−$433.0M−$618.0M$134.0M$138.0M−$297.0M−$30.0M−$1.2B
Financing Cash Flow$1.0M$4.0M$14.0M$22.0M$687.0M$0−$31.0M$948.0M$257.0M$234.0M
Net Cash Flow$0$53.0M$58.0M$126.0M−$79.0M−$19.0M$99.0M$314.0M$185.0M$203.0M
Free Cash Flow−$105.0M−$13.0M−$43.0M−$144.0M−$250.0M−$337.0M−$509.0M−$279.0M−$182.0M$411.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.64
EV / EBITDA29.10
FCF Yield-0.77%
Quick Ratio3.13
Interest Coverage0.70
Return 1Y-15.29%
Return 3Y212.30%
Return 5Y64.33%

PTC Therapeutics, Inc. (PTCT) financials — frequently asked questions

What is PTC Therapeutics, Inc.'s annual revenue?

PTC Therapeutics, Inc. (PTCT) reported annual revenue of $1.7B in its most recent fiscal year.

What is PTC Therapeutics, Inc.'s net profit?

PTC Therapeutics, Inc. (PTCT) reported net profit of $683.0M in its most recent fiscal year.

What is PTCT EV/EBITDA?

PTC Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 29.10.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
PTCT Overview PTCT Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.